Methods: A population-level Markov model was developed to evaluate the cost-effectiveness and population health impacts of 4 key interventions, individually and combined: (1) early/improved diagnosis, (2) enhanced CKD management, (3) increased use of SGLT-2 inhibitors, and (4) higher rates of pre-emptive live donor transplantation. The gene discussed is SLC5A2; the disease is chronic kidney disease.